Gyre Therapeutics
San Diego, California, United States · Biopharma, Biotechnology, Healthcare
Gyre Therapeutics is an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic diseases. The company focuses on developing treatments for inflammatory diseases and cancers. Gyre aims to leverage its capabilities for manufacturing and commercialization.
Key facts
- Headquarters
- San Diego, California, United States
- Employees
- 580
- Industries
- Biopharma, Biotechnology, Healthcare
- Status
- Public (GYRE)
- Website
- gyretx.com
- Company page
Recent activity at Gyre Therapeutics
- : Gyre Therapeutics Appoints Ying Luo as CEO and Thomas Eastling as CFO
- : SEC 8-K (5.02):
- : SEC 8-K (7.01): On September 1, 2026, Gyre Therapeutics, Inc. made an updated corporate presentation available on its website. This presentation is intended to provide shareholders and stakeholders with the latest information about the company's developments and future direction. The filing includes a reference to Exhibit 99.1, which contains the details of this presentation. The strategic implications may involve giving investors insights into potential advancements and performance metrics, although specific financial amounts or projections are not mentioned in this filing.
- : SEC 8-K (7.01): On August 26, 2026, Gyre Therapeutics, Inc. published an updated corporate presentation on its website. This presentation aims to provide stakeholders with the latest information regarding the company's initiatives and strategic direction. The contents were not deemed 'filed' under the Exchange Act, indicating that while the presentation is available for review, it does not carry the same legal implications as formal filings. This event serves to keep investors informed about the company's operations as it continues to navigate the biotech landscape.
- : SEC 8-K (5.02):
- : SEC 8-K (7.01): On June 1, 2026, Gyre Therapeutics, Inc. made available an updated corporate presentation on the Company’s website. This presentation outlines key developments and strategic initiatives undertaken by the Company and is intended to inform shareholders and investors about the Company’s current position and future outlook. While this communication does not include any financial projections, it serves as a vital tool for enhancing stakeholder understanding of Gyre Therapeutics’ objectives. The presentation is available as Exhibit 99.1 of the filing.
- : SEC 8-K (7.01):
- : SEC 8-K (7.01): On May 12, 2026, Gyre Therapeutics, Inc. announced via a press release that its subsidiary, Gyre Pharmaceuticals Co., Ltd., received notification of acceptance for its New Drug Application from the Center for Drug Evaluation of China's National Medical Products Administration for F351 (Hydronidone). This leads product candidate is aimed at treating chronic hepatitis B-induced liver fibrosis. The announcement signifies a crucial step in the drug approval process and can impact the Company's market position and potential revenue from this treatment if approved. The press release, incorporated as Exhibit 99.1, details the announcement made on this impactful date.
- : SEC 8-K (5.02): The filing reports the resignation of directors Thomas Eastling and Songjiang Ma, effective May 4, 2026, as part of the Merger Agreement. Thomas Eastling resigned from the board of directors and also stepped down as President, while Ying Luo, Ph.D., was appointed as the new Chief Executive Officer and President. This change reduces the size of the Board to seven directors and signifies a significant leadership transition. Additionally, Thomas Eastling has been appointed as Chief Financial Officer, succeeding Ruoyu Chen who also resigned on the same date, indicating a complete shift in executive leadership amidst the company's merger.
- : SEC 8-K (8.01): On March 22, 2026, Gyre Pharmaceuticals Co., Ltd., a majority indirectly owned subsidiary of Gyre Therapeutics, Inc., submitted its New Drug Application (NDA) for F351 (Hydronidone), aimed at treating chronic hepatitis B-induced liver fibrosis. This submission to the Center for Drug Evaluation of China’s National Medical Products Administration will undergo initial formatting and completeness verification. The company is preparing to collaborate with the CDE for any supplementary materials requested, with the expectation of receiving an acceptance number to initiate the technical review process. This marks a significant advancement in the Company’s product development pipeline for addressing CHB-induced liver conditions.
Gyre Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Nov 2023 | Venture | $5.0M |
Leadership
- Thomas Eastling, Chief Financial Officer
- Ying Luo, Ph.D., Chief Executive Officer
- Weiguo Yu, Executive Officer
- Ruoyu Chen, Executive Officer
- Songjiang Ma, Director
- Ying Luo, Director
- Charles Wu, Director
Verified email and direct lines for Gyre Therapeutics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Gyre Therapeutics in the news
Companies similar to Gyre Therapeutics
- AbbVie Inc. · Biopharma, Biotechnology, Healthcare, Health Care, Manufacturing, Therapeutics
- Madrigal Pharmaceuticals · Biopharma, Biotechnology, Healthcare, Health Care, Therapeutics
- Apellis Pharmaceuticals · Biopharma, Biotechnology, Healthcare, Health Care, Therapeutics
- Crinetics Pharmaceuticals · Biopharma, Biotechnology, Healthcare, Health Care, Therapeutics
- Tarsus Pharmaceuticals · Biopharma, Biotechnology, Health Care, Manufacturing, Therapeutics
About Gyre Therapeutics: questions and answers
What does Gyre Therapeutics do?
Gyre Therapeutics is an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic diseases. The company focuses on developing treatments for inflammatory diseases and cancers. Gyre aims to leverage its capabilities for manufacturing and commercialization.
Where is Gyre Therapeutics headquartered?
Gyre Therapeutics is headquartered in San Diego, California, United States.
How many employees does Gyre Therapeutics have?
Gyre Therapeutics has about 580 employees.
Has Gyre Therapeutics raised funding?
Yes. Fundz has recorded 1 funding event for Gyre Therapeutics. The most recent, $5.0M, was in Nov 2023.
Who leads Gyre Therapeutics?
Ying Luo, Ph.D. is a Chief Executive Officer at Gyre Therapeutics.
What is the latest news on Gyre Therapeutics?
On Oct 22, 2026, Gyre Therapeutics Appoints Ying Luo as CEO and Thomas Eastling as CFO
Is Gyre Therapeutics a public company?
Yes. Gyre Therapeutics is publicly traded under the ticker GYRE.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy